BREAST-001
Breast Cancer · HER2/HR/TNBC Engine · VIZASL v1
MEBICAL · EOSE Fleet · Day 95 · Real data · Cited · γ₁-anchored
MEBICAL · ONCOLOGY← RESEARCH
Breast Cancer
γ₁ floor anchor
PHASES
SORRIES
BM
NPs
Molecular Engine + Treatment
HER2+ CLEOPATRA PROVEN
Trastuzumab+pertuzumab+docetaxel. OS 57.1 vs 40.8mo.
Swain 2015 NEJM CLEOPATRA
T-DXd HER2-low DESTINY-B04 PROVEN
IHC 1+ or 2+/ISH-. ORR 52.3%. PFS 9.9 vs 5.1mo. New category.
Modi 2022 NEJM
TNBC Pembrolizumab KN-522 PROVEN
PD-L1+ neoadjuvant. pCR 64.8% vs 51.2%.
Schmid 2022 NEJM
Olaparib BRCA OlympiAD PROVEN
BRCA1/2 germline HER2-. PFS 7.0 vs 4.2mo.
Robson 2017 NEJM
CDK4/6i PALOMA-2 PROVEN
HR+/HER2-. Palbociclib+letrozole. PFS 24.8 vs 14.5mo.
Finn 2016 NEJM
Open Sorries — Click to Expand
S-1 SORRY-1 · HER2-Low Definition Shifting
S-2 SORRY-2 · Brain Mets HER2+
S-3 SORRY-3 · TNBC Outside IO Subgroup
S-4 SORRY-4 · ESR1 Mutation Resistance
S-5 SORRY-5 · CDK4/6i Resistance
Biomarkers + Signal
See Phases tab for molecular classification details. Key biomarkers noted in phase gates above.
Novel Patterns
Emerging therapies and patterns logged in PEMCLAU v11. See GREYBACK yang case corpus for yin/yang attack-defense mapping.
BREAST-001 · 4 SUBTYPES · T-DXd TRANSFORMS HER2-LOW · γ₁ = 14.134725141734693
γ₁ = 14.134725141734693